Chris at R&D Directions Insider blog spoke with both Merck's Alan Sachs and Amgen's Sean Harper down at the BIO meeting in Atlanta. Sachs is a VP of RNA Therapeutics and tells Chris that Merck isn't focusing on the delivery of RNA-based drugs but instead is looking whether RNA-based drugs make be safely taken for a chronic condition. Harper says that FDA has accepted Amgen's new drug application for denosumab to treat postmenopausal osteoporosis and bone loss from hormone ablation therapy. He adds that Amgen is also working on cancer therapies and treatments for asthma.
Down the Pike
May 19, 2009